|
2025 Journal Article Pembrolizumab (Pembro) plus R-CHOP is efficacious as first-line therapy for primary mediastinal B-cell lymphoma (PMBL) with high rates of ctdna negativity – interim efficacy analysis of the ALLG-Pacific (NHL35) trialLewis, Katharine, Blombery, Piers, Sungala, Nagendra Prasad, Giri, Pratyush, Marconi, Tamara, Cochrane, Tara, Francis, Roslyn, Lee, Sze-Ting, Ma, Chun Kei Kris, Vanguru, Vinay, Manos, Kate, Keane, Colm, Hunter, Sally, Burgess, Melinda, Kannan, Sushmitha, Carlson, Julia, Walia, Mannu, Butcher, Belinda and Cheah, Chan (2025). Pembrolizumab (Pembro) plus R-CHOP is efficacious as first-line therapy for primary mediastinal B-cell lymphoma (PMBL) with high rates of ctdna negativity – interim efficacy analysis of the ALLG-Pacific (NHL35) trial. Blood, 146 (Supplement 1), 1016-1016. doi: 10.1182/blood-2025-1016 |
|
2025 Journal Article New 18F and 68Ga tracers for PET myocardial perfusion imagingIoppolo, Joseph, Morandeau, Laurence, Hill, Leila, Rendina, Louis, Francis, Roslyn and Sadler, Alexander (2025). New 18F and 68Ga tracers for PET myocardial perfusion imaging. Nuclear Medicine and Biology, 150-151 109186, 109186-150. doi: 10.1016/j.nucmedbio.2025.109186 |
|
2025 Journal Article RECIP 1.0 more predictive of overall survival than PSMA PET progression criteria in biochemically recurrent prostate cancerMolin, Kaylee, Ong, Jeremy S. L., Werf, Steven Van Der, Francis, Roslyn J., Hassan, Ghulam Mubashar, Ebert, Martin A. and Kendrick, Jake (2025). RECIP 1.0 more predictive of overall survival than PSMA PET progression criteria in biochemically recurrent prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 1-11. doi: 10.1007/s00259-025-07592-6 |
|
2025 Journal Article ARTnet Perspectives and Contributions to TheranosticsFrancis, Roslyn J., Bailey, Dale L., Willowson, Kathy, Latter, Melissa J., Chappell, Bridget, McGill, George, Hofman, Michael S., Emmett, Louise and Scott, Andrew M. (2025). ARTnet Perspectives and Contributions to Theranostics. World Journal of Nuclear Medicine, 24 (03), 231-237. doi: 10.1055/s-0045-1812309 |
|
2025 Journal Article The effect of oral colchicine and vitamin K1 on bone metabolism in patients with diabetes mellitus: A post-hoc analysis of a 2 × 2 factorial randomized controlled trial with 18F-sodium fluoride positron emission tomographyBellinge, Jamie W., Sim, Marc, Francis, Roslyn J., Lee, Sing Ching, Chan, Dick C., Girgis, Christian M., Watts, Gerald F., Lewis, Joshua R. and Schultz, Carl J. (2025). The effect of oral colchicine and vitamin K1 on bone metabolism in patients with diabetes mellitus: A post-hoc analysis of a 2 × 2 factorial randomized controlled trial with 18F-sodium fluoride positron emission tomography. Bone, 196 117492, 117492. doi: 10.1016/j.bone.2025.117492 |
|
2025 Journal Article Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trialKwan, Edmond M., Ng, Sarah W. S., Tolmeijer, Sofie H., Emmett, Louise, Sandhu, Shahneen, Buteau, James P., Iravani, Amir, Joshua, Anthony M., Francis, Roslyn J., Subhash, Vinod, Lee, Sze-Ting, Scott, Andrew M., Martin, Andrew J., Stockler, Martin R., Donnellan, Grainne, Annala, Matti, Herberts, Cameron, Davis, Ian D., Hofman, Michael S., Azad, Arun A., Wyatt, Alexander W., Akhurst, Tim, Alipour, Ramin, Bailey, Dale L., Banks, Patricia, Beaulieu, Alexis, Campbell, Louise, Chua, Wei, Crumbaker, Megan ... Zhang, Alison Y. (2025). Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial. Nature Medicine, 2025 (8), 1-15. doi: 10.1038/s41591-025-03704-9 |
|
2025 Journal Article Prevalence and Medium-Term Outcomes of Patients with Biopsy-Proven Intermediate- to High-Risk Prostate Adenocarcinoma with Low Intraprostatic Uptake on [68Ga]Ga-PSMA-11 PET/CT in the proPSMA StudyChen, David C., Buteau, James P., Emmett, Louise, Alipour, Ramin, de Galiza Barbosa, Felipe, Roberts, Matthew J., McVey, Aoife, O’Brien, Jonathan, Levy, Sidney, Francis, Roslyn J., Lawrentschuk, Nathan, Murphy, Declan G. and Hofman, Michael S. (2025). Prevalence and Medium-Term Outcomes of Patients with Biopsy-Proven Intermediate- to High-Risk Prostate Adenocarcinoma with Low Intraprostatic Uptake on [68Ga]Ga-PSMA-11 PET/CT in the proPSMA Study. Journal of Nuclear Medicine, 66 (5), 713-718. doi: 10.2967/jnumed.124.268901 |
|
2025 Journal Article Biopsy decision for intermediate–high-risk lung nodules is significantly changed when guided by prior positron emission tomography/CT (PET/CT) results: results of the prospective PET-FIRST studyFielding, David, Sidhu, Calvin, Alkhater, Mahmoud, Alawami, Moayed, Kops, Stephan E P, van der Heijden, Erik H F M, Bashirzadeh, Farzad, Windsor, Morgan, Nixon, Elizabeth, Son, Jung Hwa, Ananda Setty, Niranjan, Pattison, David A, Fong, William, Bhatt, Manoj, Dhiantravan, Nattakorn, Ramsay, Stuart, Boots, Robert, Putt, Michael, Pratt, Gary, Bettington, Catherine, Francis, Roslyn, Thomas, Paul, Steinke, Karin and Thomas, Rajesh (2025). Biopsy decision for intermediate–high-risk lung nodules is significantly changed when guided by prior positron emission tomography/CT (PET/CT) results: results of the prospective PET-FIRST study. BMJ Open Respiratory Research, 12 (1) e002553, e002553. doi: 10.1136/bmjresp-2024-002553 |
|
2025 Journal Article An External, Independent Validation of an<i>O</i>-(2-[<sup>18</sup>F]Fluoroethyl)-l-Tyrosine PET Automatic Segmentation Network on a Single-Center, Prospective Dataset of Patients with GlioblastomaBarry, Nathaniel, Kendrick, Jake, Rowshanfarzad, Pejman, Hassan, Ghulam Mubashar, Francis, Roslyn J., Bucknell, Nicholas, Koh, Eng-Siew, Scott, Andrew M., Ebert, Martin A., Gutsche, Robin, Ciantar, Keith George, Galldiks, Norbert, Langen, Karl-Josef and Lohmann, Philipp (2025). An External, Independent Validation of anO-(2-[18F]Fluoroethyl)-l-Tyrosine PET Automatic Segmentation Network on a Single-Center, Prospective Dataset of Patients with Glioblastoma. Journal of Nuclear Medicine, 66 (6), jnumed.124.268925-953. doi: 10.2967/jnumed.124.268925 |
|
2025 Journal Article Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trialEmmett, Louise, Subramaniam, Shalini, Crumbaker, Megan, Joshua, Anthony M, Sandhu, Shahneen, Nguyen, Andrew, Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J, Goh, Jeffrey C, Tan, Thean Hsiang, Kirkwood, Ian D, Gedye, Craig, Rutherford, Natalie K, Kumar, Aravind S Ravi, Pook, David, Ramdave, Shakher, Nadebaum, David P, Voskoboynik, Mark, Redfern, Andrew D, Macdonald, William, Krieger, Laurence, Schembri, Geoff, Chua, Wei, Lin, Peter, Horvath, Lisa, Bastick, Patricia, Butler, Patrick ... Bills, Madison (2025). Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial. The Lancet Oncology, 26 (3), 291-299. doi: 10.1016/s1470-2045(25)00009-9 |
|
2025 Journal Article Evaluating the prognostic value of radiomics and clinical features in metastatic prostate cancer using [68Ga]Ga-PSMA-11 PET/CTMolin, Kaylee, Barry, Nathaniel, Gill, Suki, Hassan, Ghulam Mubashar, Francis, Roslyn J., Ong, Jeremy S. L., Ebert, Martin A. and Kendrick, Jake (2025). Evaluating the prognostic value of radiomics and clinical features in metastatic prostate cancer using [68Ga]Ga-PSMA-11 PET/CT. Physical and Engineering Sciences in Medicine, 48 (1), 329-341. doi: 10.1007/s13246-024-01516-8 |
|
2025 Journal Article Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trialEmmett, Louise, Papa, Nathan, Subramaniam, Shalini, Crumbaker, Megan, Nguyen, Andrew, Joshua, Anthony M, Sandhu, Shahneen, Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J, Goh, Jeffrey C, Pattison, David A, Tan, Thean Hsiang, Kirkwood, Ian D, Ayati, Narjess, Niu, Claire, Hofman, Michael S, Martin, Andrew James, Thomas, Hayley, Davis, Ian D and Stockler, Martin R (2025). Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial. The Lancet Oncology, 26 (9), 1168-1177. doi: 10.1016/S1470-2045(25)00339-0 |
|
2025 Journal Article Deep learning-based PSMA PET segmentation repeatability: A post-hoc analysis of a single-center, prospective, test–retest trialKendrick, Jake, Francis, Roslyn J., Hassan, Ghulam Mubashar, Ong, Jeremy S. L., Jeraj, Robert, Barry, Nathaniel and Ebert, Martin A. (2025). Deep learning-based PSMA PET segmentation repeatability: A post-hoc analysis of a single-center, prospective, test–retest trial. Radiologia Medica. doi: 10.1007/s11547-025-02137-1 |
|
2025 Journal Article Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/- UV1 telomerase vaccineThunold, Solfrid, Hernes, Eivor, Farooqi, Saima, Öjlert, Åsa Kristina, Francis, Roslyn J., Nowak, Anna K., Szejniuk, Weronika Maria, Nielsen, Søren Steen, Cedres, Susana, Perdigo, Marc Simo, Sørensen, Jens Benn, Meltzer, Carin, Mikalsen, Lars Tore Gyland, Helland, Åslaug, Malinen, Eirik and Haakensen, Vilde Drageset (2025). Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/- UV1 telomerase vaccine. European Journal of Nuclear Medicine and Molecular Imaging, 52 (2), 693-707. doi: 10.1007/s00259-024-06853-0 |
|
2025 Journal Article Fluorodeoxyglucose Positron Emission Tomography Detects Persistent Arterial Inflammation After Symptomatic COVID-19Espedal, Heidi, Verma, Shipra, Roy, Ambuj, Lan, Nick S.R., Mohd, Sheeraz, Bartlett, Benjamin, Ali, Kamar, Ward, Natalie C., Ebert, Martin A., Chan, Dick C., Watts, Gerald F., Dwivedi, Girish and Francis, Roslyn J. (2025). Fluorodeoxyglucose Positron Emission Tomography Detects Persistent Arterial Inflammation After Symptomatic COVID-19. Heart Lung and Circulation, 34 (9), 969-976. doi: 10.1016/j.hlc.2025.03.005 |
|
2025 Journal Article Persistent lung and vascular inflammation in mild to moderate COVID-19 survivors detected by ¹⁸F-FDG PET/CT: A quantitative imaging study with implications for cardiovascular riskVerma, Shipra, Lan, Nick S. R., Espedal, Heidi, Ong, Jeremy, Roy, Ambuj, Ahmad, Adilah, Ali, Kamar, Ward, Natalie C., Patel, Sanjay, Parizel, Paul M., Francis, Roslyn J. and Dwivedi, Girish (2025). Persistent lung and vascular inflammation in mild to moderate COVID-19 survivors detected by ¹⁸F-FDG PET/CT: A quantitative imaging study with implications for cardiovascular risk. European Journal of Nuclear Medicine and Molecular Imaging. doi: 10.1007/s00259-025-07656-7 |
|
2024 Journal Article The Australian traumatic brain injury initiative: systematic review and consensus process to determine the predictive value of pre-existing health conditions for people with moderate-severe traumatic brain injuryAntonic-Baker, Ana, Auvrez, Clarissa, Tao, Gerard, Bagg, Matthew K., Gadowski, Adelle, McKimmie, Ancelin, Hicks, Amelia J., Hill, Regina, Romero, Lorena, Ponsford, Jennie L., Lannin, Natasha A., Gabbe, Belinda J., Cameron, Peter A., Cooper, D. Jamie, Rushworth, Nick, Fitzgerald, Melinda, O'Brien, Terence J., Alexander, Tara, Anderson, Vicki, Armstrong, Elizabeth, Babl, Franz E., Balogh, Zsolt J., Barlow, Karen M. (AUS-TBI Initiative Investigators group member), Bellapart, Judith, Bidargaddi, Niranjan, Bosio, Erika, Bragge, Peter, Bynevelt, Michael, Caeyenberghs, Karen ... Zeeman, Heidi (2024). The Australian traumatic brain injury initiative: systematic review and consensus process to determine the predictive value of pre-existing health conditions for people with moderate-severe traumatic brain injury. Journal of Neurotrauma, 42 (21-22), 2047-2061. doi: 10.1089/neu.2023.0462 |
|
2024 Journal Article Assessing the heterogeneity of response of [68Ga] Ga-PSMA-11 PET/CT lesions in patients with biochemical recurrence of prostate cancerDell'Oro, Mikaela, Huff, Daniel T., Lokre, Ojaswita, Kendrick, Jake, Munian Govindan, Rajkumar, Ong, Jeremy S. L., Ebert, Martin A., Perk, Timothy G. and Francis, Roslyn J. (2024). Assessing the heterogeneity of response of [68Ga] Ga-PSMA-11 PET/CT lesions in patients with biochemical recurrence of prostate cancer. Clinical Genitourinary Cancer, 22 (5) 102155, 102155. doi: 10.1016/j.clgc.2024.102155 |
|
2024 Journal Article Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 studyAzad, Arun A, Bressel, Mathias, Tan, Hsiang, Voskoboynik, Mark, Suder, Aneta, Weickhardt, Andrew J, Guminski, Alexander, Francis, Roslyn J, Saghebi, Javad, Dhiantravan, Nattakorn, Joshua, Anthony M, Emmett, Louise, Horvath, Lisa, Murphy, Declan G, Hsiao, Edward, Balakrishnar, Bavanthi, Lin, Peter, Redfern, Andrew, Macdonald, William, Ng, Siobhan, Lee, Sze-Ting, Pattison, David A, Nadebaum, David, Kirkwood, Ian D, Hofman, Michael S, Akhurst, T, Alipour, R, Au, L, Banks, P ... Ratnayake, L (2024). Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study. The Lancet Oncology, 25 (10), 1267-1276. doi: 10.1016/s1470-2045(24)00440-6 |
|
2024 Journal Article Training and assessing convolutional neural network performance in automatic vascular segmentation using Ga-68 DOTATATE PET/CTParry, R., Wright, K., Bellinge, J. W., Ebert, M. A., Rowshanfarzad, P., Francis, R. J. and Schultz, C. J. (2024). Training and assessing convolutional neural network performance in automatic vascular segmentation using Ga-68 DOTATATE PET/CT. International Journal of Cardiovascular Imaging, 40 (9), 1847-1861. doi: 10.1007/s10554-024-03171-2 |
